Q-omics provides the consensus-scored CHKB-DT profile across patient tissues and cancer cell-line models. CHKB-DT expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHKB-DT is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, CHKB-DT RNA expression shows 15,138 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where CHKB-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHKB-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHKB-DT survival associations across molecular data types. CHKB-DT RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHKB-DT RNA expression–survival associations across cancer types. High CHKB-DT expression shows unfavorable associations in KIRC, LIHC, UVM, UCS and ACC, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHKB-DT RNA expression.
This table summarizes CHKB-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CHKB-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHKB-DT shows higher tumor expression in BLCA, HNSC, LUAD, LIHC, STAD and KIRC. The BLCA box plot shows higher CHKB-DT RNA expression in tumor versus normal tissue (log2 FC = +0.982, t-test p < 0.001).
This table shows molecular features associated with CHKB-DT in patient tissues and cancer cell lines. In patient samples, CHKB-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
